The findings present in this study confirmed that high levels of CD56 expression are associated with adverse clinical outcomes in AML patients, indicating that CD56 could be considered as a prognostic marker for a more precise stratification of non-M3 AML patients. Here, NCAM1 is linked to acute myeloid leukemia.